$35.91
+0.38
(+1.07%)▲
1.91%
Downside
Day's Volatility :3.76%
Upside
1.89%
28.24%
Downside
52 Weeks Volatility :48.7%
Upside
28.51%
Period | Cg Oncology Inc. | Index (Russel 2000) |
---|---|---|
3 Months | 15.8% | 0.0% |
6 Months | -0.99% | 0.0% |
1 Year | -3.39% | 0.0% |
3 Years | -3.39% | -26.4% |
Market Capitalization | 2.4B |
Wall Street Target Price | 68.2 |
Profit Margin | 0.0% |
Operating Margin TTM | -4247.45% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 539.0K |
Revenue Per Share TTM | 0.04 |
Quarterly Revenue Growth YOY | 172.70000000000002% |
Gross Profit TTM | 0.0 |
EBITDA | -68.2M |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.59 |
EPS Estimate Next Year | -1.89 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 89.92%
Sell
Neutral
Buy
Cg Oncology Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Cg Oncology Inc. | -0.14% | -0.99% | -3.39% | -3.39% | -3.39% |
Regeneron Pharmaceuticals, Inc. | -16.85% | -11.85% | 3.27% | 29.37% | 171.22% |
Biontech Se | -6.94% | 20.23% | 16.39% | -62.26% | 487.66% |
Alnylam Pharmaceuticals, Inc. | 1.63% | 79.81% | 63.67% | 58.45% | 198.57% |
Vertex Pharmaceuticals Incorporated | 3.87% | 17.46% | 25.23% | 149.18% | 136.25% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Cg Oncology Inc. | NA | NA | NA | -1.59 | 0.0 | 0.0 | NA | NA |
Regeneron Pharmaceuticals, Inc. | 20.75 | 20.75 | 1.18 | 44.77 | 0.17 | 0.08 | NA | 242.47 |
Biontech Se | 160.8 | NA | 0.04 | -2.76 | -0.03 | -0.02 | NA | 80.22 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.39 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.21 | 0.16 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Cg Oncology Inc. | Buy | $2.4B | -3.39% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $101.7B | 171.22% | 20.75 | 32.04% |
Biontech Se | Buy | $27.1B | 487.66% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 198.57% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $122.9B | 136.25% | 32.84 | -4.74% |
Cg Oncology Inc.’s price-to-earnings ratio stands at None
Read MoreOrganization | Cg Oncology Inc. |
Employees | 61 |
CEO | Mr. Arthur Kuan |
Industry | Miscellaneous |
Ishares Long-term Corporate Bond Etf
$35.91
+1.07%
Dropbox, Inc.
$35.91
+1.07%
Ark Innovation Etf
$35.91
+1.07%
Proshares Ultrapro Short Qqq
$35.91
+1.07%
Hafnia Ltd
$35.91
+1.07%
Vanguard Russell 1000 Etf
$35.91
+1.07%
Evolent Health, Inc. - Class A Shares
$35.91
+1.07%
Apogee Therapeutics
$35.91
+1.07%
Cleanspark Inc
$35.91
+1.07%